Industry News
Pharmaceutical Industry News
How the Iran War Has Rippled Across the World
Deflated balloons? Pricier sugar? The fighting in the Middle East has played out across the world in sometimes surprising ways.
With a second phase 3 win for…
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion and putting more color on its filing plans with the FDA.
Promotional materials for a…
Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.
After notching a phase 2 trial…
After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq is one step closer to potentially becoming a first-in-class treatment for children.
The labor union of Samsung…
The labor union of Samsung Biologics has secured the votes needed to strike, signaling a potential escalation in an impasse over what the union has branded “[u]nresolved governance failures and rigid labor policies” at the
Takeda has started a workforce…
Takeda has started a workforce reduction in the U.S., plotting to cut 634 jobs, as the company aims to save more than $1.26 billion in annual costs.
Biogen’s Spinraza represented a…
Biogen's Spinraza represented a major advance in treating SMA upon its FDA approval nearly a decade ago. It has since ceded some of its competitive positioning as new entrants made their way onto the market,
There’s no need to dive fast and…
There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division.
Rocket has announced that the FDA…
Rocket has announced that the FDA signed off on an accelerated approval for its hematopoietic stem cell-based gene therapy, Kresladi, also known as marnetegragene autotemcel, to treat certain children with severe leukocyte adhesion deficiency-1.
Takeda is launching a…
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's semaglutide reached India in chaotic fashion. Gilead Sciences is paying up to $2.2 billion to purchase a Chinese
How to Turn a Chicken Egg Into a Drug Factory
A biotech start-up is testing a novel way of efficiently producing pharmaceutical drugs.
CVC Capital Partners has offered…
CVC Capital Partners has offered to buy out the remaining shares in Italian pharma Recordati for 10.9 billion euros ($12.6 billion). The investment firm, which already has a 47% stake in Recordati, intends to delist
Addressing pressing questions…
Addressing pressing questions about the upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday outlined a path for Amvuttra to become the revenue leader in an expansive ATTR-CM space of more than 75,000 U.S.-treated
After becoming a prominent public…
After becoming a prominent public face of the CDC’s revamped Advisory Committee on Immunization Practices, Robert Malone, M.D., has reportedly stepped down from his role, citing mounting drama in recent weeks.
The new company, looking to…
The new company, looking to eliminate costly manufacturing bottlenecks by producing biologic medicines in chicken eggs, has now lined up a commercial taker.
Roche’s Genentech is backing…
Roche’s Genentech is backing this year's Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in previous years.
Florida Restores Access to Low-Cost H.I.V. Medications After Uproar
A short-term funding bill enacted this week will ensure that more than 12,000 Floridians do not lose access to a program that helps pay for H.I.V. medications.
HSBC’s downgrade of Lilly is…
HSBC’s downgrade of Lilly is raising new questions about the GLP-1 market and the outlook for obesity treatments. The Fierce Pharma team breaks down what it could mean and what comes next.
A new report from Assembled…
A new report from Assembled Intelligence and inVibe sheds light on how HCPs are using digital technologies in their work—and what that means for marketers.
The FDA has given the all-clear to…
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior lines of systemic treatment, at least